GlassScriptPhysician profile
Lisa Higgins
NPI 1477956688
$310,843.80
in general payments reported to CMS, 2019-2025
27 companies · $57K in 2025
The $57K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52K · 2022: $53K · 2023: $56K · 2024: $93K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $166K · Travel and Lodging: $25K · Food and Beverage: $8,977 · Honoraria: $3,400 · Consulting Fee: $1,563 · Education: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $166,199.30 |
| Travel and Lodging | $25,254.23 |
| Food and Beverage | $8,976.99 |
| Honoraria | $3,400.00 |
| Consulting Fee | $1,562.50 |
| Education | $650.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $160,622.57 | 2021-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $95,024.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $46,199.49 | 2022-2025 | Korlym |
| Amgen INC. | $2,617.77 | 2021-2025 | Repatha, Tezspire, Evenity |
| Insulet Corporation | $2,261.48 | 2021-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $1,237.77 | 2021-2024 | Farxiga, Tezspire, Airsupra |
| Lilly USA, LLC | $568.65 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $535.12 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $365.74 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $211.39 | 2022-2025 | |
| Dexcom, INC. | $208.74 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $166.35 | 2021-2024 | Nexletol |
| Abbott Laboratories | $157.96 | 2021-2024 | Freestyle Libre 3 |
| Abbvie INC. | $136.45 | 2021-2023 | |
| Edwards Lifesciences Corporation | $115.69 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $85.94 | 2021-2023 | |
| Mannkind Corporation | $55.76 | 2023 | Afrezza |
| Becton, Dickinson and Company | $44.66 | 2021 | |
| Tandem Diabetes Care, INC. | $42.49 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $36.84 | 2021 | |
| Kyowa Kirin, INC. | $25.47 | 2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.23 | 2021 | |
| Vistapharm, INC. | $24.13 | 2021 | |
| Merck Sharp & Dohme LLC | $23.26 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.80 | 2021 | |
| Nevro Corp. | $16.41 | 2022 | |
| Qiagen, LLC | $14.54 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.